AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00388804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
Study NCT00388804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg By Mouth (PO) Daily
Study NCT00388804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: 22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
Study NCT00388804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: 10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
Study NCT00388804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: 250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
Study NCT00388804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
Study NCT04165044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
Description: The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
Study NCT04165044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft plus Coronally Advanced Flap
Description: The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
Study NCT03223051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor assessment
Description: An occupational therapist install the patient sitting in front of the test board and tell him the instructions
Study NCT04243512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Restrict food and beverage intake (except water) to a 10-hour window
Study NCT00092092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast chewable tablets
Description: Montelukast sodium 5 mg chewable tablets
Study NCT00092092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide inhaler
Description: Budesonide 200 mcg inhalation powder
Study NCT00092092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to montelukast chewable tablets
Description: Placebo chewable tablets
Study NCT00092092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to budesonide inhaler
Description: Placebo inhalation powder
Study NCT00994175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT00994175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01894997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulator
Study NCT01894997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Impulse System Model 6000
Study NCT02760147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Over Support
Description: Pressure Support Level upward by 50%, 2 hours
Study NCT02760147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Under Support
Description: Pressure Support Level downward by 50%, 2 hours
Study NCT02760147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Over Level
Description: PEEP Level upward by 50%, 2 hours
Study NCT02760147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Under Level
Description: PEEP Level downward by 50%, 2 hours
Study NCT01395069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1%
Description: 1 drop QID for 1 month
Study NCT01395069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5%
Description: 1 drop QID for 1 month
Study NCT01395069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sterile saline drops)
Description: 1 drop QID for 1 month
Study NCT03380195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon juice
Description: Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
Study NCT03380195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sport drink
Description: Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
Study NCT03380195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar water
Description: Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
Study NCT03380195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subject drinks 355ml of water 1 hour prior to submaximal exercise
Study NCT01833208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01833208 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo single-fraction radiation therapy
Study NCT02444780 — intervention group
Intervention type: PROCEDURE
Intervention: no intervention, blood is sampled for routine
Description: no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
Study NCT04949802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViaLase Laser
Description: ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
Study NCT02177253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide / Salbutamol
Study NCT02177253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation solution
Study NCT02177253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Study NCT02177253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT Inhalation Aerosol
Study NCT02177253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Aerosol
Study NCT03427697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality and accommodation relax techniques in combination
Description: The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous placebo
Description: normal saline
Study NCT01932762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg every day (QD) orally
Study NCT01932762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg QD orally
Study NCT01932762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: microcrystalline cellulose
Study NCT01511497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
Study NCT01511497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous, normal saline
Study NCT00497874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Description: Stage-based manual and three computer-tailored reports
Study NCT04445298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transepidermal water loss
Description: We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
Study NCT03917277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound
Description: Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal
Study NCT00560703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-101 (doxycycline, USP) capsules
Description: 40mg, once per day for 84 days
Study NCT00560703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar capsule
Study NCT01315522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ComVi stent
Description: Endoscopic insertion of ComVi stent
Study NCT01315522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered SEMS
Description: Endoscopic insertion of uncovered SEMS
Study NCT02779075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
Study NCT02779075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
Study NCT01104987 — intervention group
Intervention type: DRUG
Intervention: alendronate
Description: One tablet of alendronate à 70 mg once a week during two years.
Study NCT01765816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Study NCT01765816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: high intensity interval training
Study NCT01765816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate intensity training
Study NCT01765816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training
Study NCT03374488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
Study NCT03374488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
Study NCT03374488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.
Study NCT03374488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study NCT04659057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Lidocaine
Description: will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
Study NCT04659057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized dexmedetomidine
Description: will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
Study NCT04659057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized lidocaine and dexmedetomidine
Description: will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
Study NCT04659057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will receive nebulized saline 0.9% (5 ml) as control group.
Study NCT02333500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory workshop
Description: olfactory workshop
Study NCT02333500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: other workshop
Description: other workshop: discussion group, dance and body Expression
Study NCT02333500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: control group
Study NCT04445298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
Study NCT04445298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Study NCT00616447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: 6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
Study NCT00616447 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo sham
Description: Sham treatment will mimic active treatment mentioned above.
Study NCT03051438 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subxiphoid uniportal VATS
Description: Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
Study NCT04445298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial PCR swab
Description: Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Study NCT02723097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 RP
Study NCT00500032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood draw
Description: Blood draw from subjects previously vaccinated in 6108A1-500 trial
Study NCT00349466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: Orally CF101 1mg
Study NCT00349466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally matching Placebo
Study NCT02358668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTI320
Description: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
Study NCT03051438 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Three-port VATS
Description: The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
Study NCT02358668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BTI320 matching placebo
Description: Placebo
Study NCT00234598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing only
Description: Toothbrushing three times per 24 hours without chlorhexidine
Study NCT00234598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine only
Description: Chlorhexidine oral rinse twice per 24 hours without toothbrushing
Study NCT00234598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing and Chlorhexidine
Description: Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Study NCT02366143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Study NCT02419417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days
Study NCT02419417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02592213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell-assisted lipotransfer
Description: Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
Study NCT01149122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/Oxaliplatin
Description: GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
Study NCT01149122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)
Description: GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
Study NCT04253938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.